Mark Froimson Biography and Net Worth

Mark I. Froimson, MD is the past President of the American Association of Hip and Knee Surgeons (AAHKS). Prior to that, he was the Executive Vice President and Chief Clinical Officer of Trinity Health, a major national non-profit Catholic healthcare system comprising 93 hospitals in 22 states. Before his executive leadership position at Trinity Health, Dr. Froimson was president and chief executive officer of Euclid Hospital, a Cleveland Clinic Hospital. Dr. Froimson served as a staff surgeon in the Department of Orthopedic Surgery at the Cleveland Clinic for over 16 years, during which time he held a variety of leadership positions including president of the professional staff, vice chair of the Orthopedic and Rheumatologic Institute, and member of the Board of Governors and Board of Trustees.

Dr. Froimson received a B.S. in philosophy from Princeton University, an M.D. from Tulane University School of Medicine and an MBA from the Weatherhead School of Business at Case Western Reserve University.

What is Mark Froimson's net worth?

The estimated net worth of Mark Froimson is at least $360,232.97 as of August 12th, 2024. Dr. Froimson owns 14,473 shares of Pacira BioSciences stock worth more than $360,233 as of April 2nd. This net worth estimate does not reflect any other investments that Dr. Froimson may own. Learn More about Mark Froimson's net worth.

How do I contact Mark Froimson?

The corporate mailing address for Dr. Froimson and other Pacira BioSciences executives is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. Pacira BioSciences can also be reached via phone at (813) 553-6680 and via email at susan.mesco@pacira.com. Learn More on Mark Froimson's contact information.

Has Mark Froimson been buying or selling shares of Pacira BioSciences?

Mark Froimson has not been actively trading shares of Pacira BioSciences during the last quarter. Most recently, on Monday, August 12th, Mark Froimson bought 1,400 shares of Pacira BioSciences stock. The stock was acquired at an average cost of $11.58 per share, with a total value of $16,212.00. Following the completion of the transaction, the director now directly owns 14,473 shares of the company's stock, valued at $167,597.34. Learn More on Mark Froimson's trading history.

Who are Pacira BioSciences' active insiders?

Pacira BioSciences' insider roster includes Marcelo Bigal (Director), Mark Froimson (Director), Mark Kronenfeld (Director), Frank Lee (Chief Executive Officer & Director), Donald Manning (Insider), Max Reinhardt (Insider), Charles Reinhart, III (CFO), Lauren Riker (VP), Jonathan Slonin (Chief Medical Officer), David Stack (CEO), Andreas Wicki (Director), Kristen Williams (Insider), Kristen Williams (Chief Administrative Officer & Secretary), and Roy Winston (Insider). Learn More on Pacira BioSciences' active insiders.

Are insiders buying or selling shares of Pacira BioSciences?

In the last twelve months, Pacira BioSciences insiders bought shares 3 times. They purchased a total of 11,176 shares worth more than $136,240.40. In the last twelve months, insiders at the sold shares 10 times. They sold a total of 23,974 shares worth more than $653,601.25. The most recent insider tranaction occured on January, 6th when insider Jonathan Slonin sold 879 shares worth more than $16,173.60. Insiders at Pacira BioSciences own 6.4% of the company. Learn More about insider trades at Pacira BioSciences.

Information on this page was last updated on 1/6/2025.